These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 25448761)
1. Improving the predictive value of interventional animal models data. Zeiss CJ Drug Discov Today; 2015 Apr; 20(4):475-82. PubMed ID: 25448761 [TBL] [Abstract][Full Text] [Related]
2. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665 [TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of action of Alzheimer medications]. Alhainen K Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001 [No Abstract] [Full Text] [Related]
4. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874 [No Abstract] [Full Text] [Related]
5. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic. Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371 [TBL] [Abstract][Full Text] [Related]
6. Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008. Lazzeroni LC; Halbauer JD; Ashford JW; Noda A; Hernandez B; Azor V; Hozack N; Hasson N; Henderson VW; Yesavage JA; Tinklenberg JR J Alzheimers Dis; 2013; 36(4):791-8. PubMed ID: 23703151 [TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease. Neumeister KL; Riepe MW J Alzheimers Dis; 2012; 30(2):245-51. PubMed ID: 22414570 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy no advantage in Alzheimer's treatment. Harv Health Lett; 2012 Jun; 37(8):8. PubMed ID: 22774260 [No Abstract] [Full Text] [Related]
9. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Dong H; Csernansky CA; Martin MV; Bertchume A; Vallera D; Csernansky JG Psychopharmacology (Berl); 2005 Aug; 181(1):145-52. PubMed ID: 15778881 [TBL] [Abstract][Full Text] [Related]
10. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil. Woodruff-Pak DS; Tobia MJ; Jiao X; Beck KD; Servatius RJ Neuropsychopharmacology; 2007 Jun; 32(6):1284-94. PubMed ID: 17119537 [TBL] [Abstract][Full Text] [Related]
11. Donepezil for Alzheimer's disease. Benjamin B; Burns A Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763 [TBL] [Abstract][Full Text] [Related]
12. Use of memantine for the treatment of dementia. Lo D; Grossberg GT Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192 [TBL] [Abstract][Full Text] [Related]
13. Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. Ota H; Ogawa S; Ouchi Y; Akishita M Exp Gerontol; 2015 Dec; 72():109-16. PubMed ID: 26408226 [TBL] [Abstract][Full Text] [Related]
14. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395 [TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
16. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area. Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135 [TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693 [TBL] [Abstract][Full Text] [Related]
18. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Hashimoto M; Kazui H; Matsumoto K; Nakano Y; Yasuda M; Mori E Am J Psychiatry; 2005 Apr; 162(4):676-82. PubMed ID: 15800138 [TBL] [Abstract][Full Text] [Related]
19. Donepezil use in Alzheimer disease. Barner EL; Gray SL Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]